Summary Loss of heterozygosity (LOH) frequently occurs in squamous cell carcinomas of the uterine cervix and indicates the probable sites of tumour-suppressor genes that play a role in the development of this tumour. To define the localization of these tumour-suppressor genes, we studied loss of heterozygosity in 64 invasive cervical carcinomas (stage IB and IIA) using the polymerase chain reaction with 24 primers for polymorphic repeats of known chromosomal localization. Chromosomes 3, 11, 13, 16 and 17, in particular, were studied. LOH was frequently found on chromosome 11, in particular at 11 q22 (46%) and 11 q23.3 (43%). LOH on chromosome 11p was not frequent. On chromosome 17p1 3.3, a marker (Dl 7S513) distal to p53 showed 38% LOH, whereas p53 itself showed only 20% LOH. On the short arm of chromosome 3, LOH was frequently found (41%) at 3p21.1. The f-catenin gene is located in this chromosomal region. Therefore, expression of f-catenin protein was studied in 39 cases using immunohistochemistry. Staining of 1-catenin at the plasma membrane of tumour cells was present in 38 cases and completely absent in only one case. The tumour-suppressor gene on chromosome 3p21.1 may be ,B-catenin in this one case, but (an)other tumour-suppressor gene(s) must also be present in this region. For the other chromosomes studied, 1 3q (BRCA-2) and 16q (E-cadherin), only sporadic losses (< 15% of cases) were found. Expression of E-cadherin was found in all of 37 cases but in six cases the staining was very weak. No correlation was found between clinical and histological parameters and losses on chromosome 3p, 1 1 q and 1 7p. In addition to LOH, microsatellite instability was found in one tumour for almost all loci and in eight tumours for one to three loci. In conclusion, we have identified three loci with frequent LOH, which may harbour new tumour-suppressor genes, and found microsatellite instability in 14% of cervical carcinomas.
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Keywords: cervical carcinoma; allelic imbalance; 1-catenin; microsatellite instability; tumour-suppressor gene; E-cadherin The involvement of human papillomavirus (HPV) in the development of carcinomas of the uterine cervix has been firmly established. Because HPV infection does not always lead to cervical cancer, other genetic alterations must also play a role in tumour development. Loss of heterozygosity (LOH), pointing to a role for tumour-suppressor genes, oncogene amplification and point mutations are all thought to be involved, but there is as yet no complete picture of the relative role for each of these genetic changes in cervical carcinomas. To play a role in tumorigenesis, both copies of a tumour-suppressor gene have to be inactivated. Usually, one allele is lost by a small inactivating mutation and the second by loss of heterozygosity. Loss of one allele in a chromosome region may therefore point to the presence of a tumour-suppressor gene in that region. Such chromosome losses can be detected by polymorphic markers. Different studies have reported a high incidence of LOH on chromosomes 3p, lIp and 1 lq. However, a detailed deletion map of these areas has not been made yet.
Seven different groups (Yokota et al, 1989; Chung et al, 1992; Jones and Nakamura, 1992; Kohno et al, 1993; Karlsen et al, 1994; Mitra et al, 1994; Mullokandov et al, 1996; Rader et al, 1996) found LOH on chromosome 3 in cervical carcinomas. The regions mapped by these investigators include 3p2l-p22, where Hengel et al, 1995; Trent et al, 1995; Nollet et al, 1996) . O-Catenin is a structural mediator for the attachment of the cytoskeletal actin filaments to cellular adhesion molecules, i.e. cadherins, in particular E-cadherin (Jou et al 1995; Kawanishi et al, 1995; Rubinfeld et al, 1995) . O-Catenin also complexes with the APC gene product, a tumour-suppressor gene mutated in hereditary polyposis coli and sporadic colorectal tumours (Rubinfeld et al, 1993; Su et al, 1993; Hulsken et al, 1994) . In normal cells, APC binds together with GSK-3, to ,-catenin and degrades it. O-Catenin can be deregulated by mutations in APC or in P-catenin itself. This results in the accumulation of ,-catenin, activating its role in signalling Morin et al, 1997; Rubinfeld et al, 1997) .
The involvement of chromosome 11 in cervical cancer has been reported by several groups. Hampton et al (1994) found the smallest region of overlapping LOH at 1 lq22-24. Bethwaite et al (1995) found LOH on 1 1q23, but only with one marker in this region. Misra and Saxon (Misra and Srivatsan, 1989; Saxon et al, 1986) used HeLa cells, which had lost part of chromosome 11, to fuse them with fibroblast hybrids that contained part or all of chromosome 11. By transferring a normal complete copy of chromosome 11, the HeLa cells became non-tumorigenic. This suggests that chromosome 11 harbours genes that are involved in the suppression of HeLa cell tumorigenicity.
Many investigators (Kaelbling et al, 1992; Mitra et al, 1994; Havre et al, 1995; Hoppe-Seyler and Butz, 1995; Mansur et al, 1995; Mullokandov et al, 1996) have studied the short arm of chromosome 17 for the p53 gene, which may be involved in cervical carcinomas through its interaction with HPV-E6 oncoproteins. p53 point mutations are infrequent (< 10%) in clinical samples of squamous cell carcinomas of the uterine cervix, whereas p53 point mutations were seen more often in adenocarcinoma (30%) (Fujita et al, 1992; Jiko et al, 1994; Schneider et al, 1994) . Park et al (1995) detected LOH at l7pl3.3 in eight (40%) out of 20 heterozygous cervical carcinomas, with at least one of the two markers D17S34 or D17S5. This region also shows a high incidence of LOH in other tumours, such as tumours of the bladder, ovary and breast (Cornelis et al, 1994; Morris et al, 1995) . In this study, we analysed a series of 64 squamous cervical carcinomas for the presence of LOH on chromosomes 3, 11, 13, 16, and 17 for 24 polymorphic repeats. Chromosomes 3 and 11 were studied in more detail, using an extra set of four polymorphic DNA markers on chromosome 3p, and nine on chromosome 1 lq, to determine the smallest region of overlap. We also studied by immunohistochemistry the expression of the protein products of two candidate (tumour-suppressor) genes on chromosome 3p and 16q, the I-catenin and E-cadherin gene. All allelic losses found on chromosomes 3, 11 and 17 were correlated to each other and with clinical parameters, including FIGO stage, lymph node status and histological parameters.
MATERIALS AND METHODS Materials
From 60 patients with squamous cell carcinoma and four patients with adenocarcinoma of the uterine cervix operated on between 1984 and 1995, tissue blocks were retrieved from the archives of the Department of Pathology, University Hospital Leiden. The
Polymerase chain reaction (PCR) technique
Primers for polymorphic repeats (Table 1 , mostly CA repeats and some tetranucleotide repeats) were chosen on the basis of their heterozygosity percentage, location and allele length from the genome database. The intragenic ,B-catenin primers were kindly provided by F Nollet, University of Ghent, Belgium. A standard PCR was carried out in a 12-jil reaction volume containing 10 ng of DNA, 5 pmol of each primer, 2 mm dNTP-C, 0.1 mg ml-1 BSA, Taq polymerase buffer (containing 10 mmol Tris, 1.5 mm magnesium chloride, 50 mm potassium chloride, 0.01% (w/v) gelatin, 0.1% Triton), 0.06 units SuperTaq polymerase (HT Biotechnology, Cambridge), and 1 jiCi [a-32P]-CTP. The amplification reactions were carried out for 33 cycles at 55°C annealing temperature. The PCR products were denatured in formamide, electrophoresed on a 6% denaturing polyacrylamide gel, and visualized by autoradiography for 14-18 h at room temperature. Absence of or a very strong decrease in signal intensity of one allele in tumour DNA compared with constitutional DNA by visual examination was considered evidence for LOH. When a decrease in signal intensity was not convincing, the cases were measured on a Molecular Dynamics Phosphorlmager 445SI. Molecular Dynamics ImageQuant Software was used for quantification of PCR products. An allelic imbalance factor was calculated by the quotient of the peak ratios from constitutional and tumour DNA (Ni :N2/T1 :T2). In cases where the allele ratio calculated by this equation was beneath 1.00, we converted the ratio to l/[Nl:N2/T1 :T2]. An allelic imbalance of 1.8 or lower is interpreted as retention, whereas an allelic imbalance of 1.8 or higher is considered as a LOH event Imbalance factor
Chromosome 17 D17S513 TP53 D17S520 D17S578 D17S855 Phosphate-buffered saline (PBS) with 1% BSA was used as diluent for all antibodies. All washes consisted of 3 x 5 min.
Paraffin sections were deparaffinized, rehydrated and endogenous peroxidase was quenched with 0.3% hydrogen peroxide in methanol for 20 mmn. Before incubation with the primary antibodies the slides were subjected to antigen retrieval using a boiling solution of 0.01 M citrate buffer pH 6.0 (Cattoretti et al, 1993) in a microwave oven at 700 W and cooled down to room temperature in citrate buffer for 2 h. After washing in PBS, an ovemight incubation followed with mouse monoclonals anti-human ,B-catenin (1:4000, Transduction Laboratories) and anti-E-cadherin, clone HECD-1 (1:500, Zymed). Biotin-labelled rabbit anti-mouse immunoglobulins and a biotinylated HRP-streptavidin complex (both Dako) were subsequently applied for 30 min each with washes in PBS in between. A 0.05% solution of diaminobenzidine (Sigma) with 0.0015% hydrogen peroxide was applied for 10 min to visualize the immune aggregates. Mayers' haematoxylin was used for counterstaining of the slides.
Brown staining of the plasma membrane indicated a positive staining for both antibodies. Normal squamous epithelium, when present, served as an internal positive control. Omitting the primary antibody on serial slides served as a negative control.
Immunohistochemical stainings of P-catenin and E-cadherin were scored semiquantitatively. The percentage of tumour cells stained positive were scored as 0 = no positive tumour cells; 1 = 1-25%; 2 = 26-50%; 3 = 51-75%; 4 = 76-100%. The intensity was estimated in comparison with the control and scored as 0 = absence of staining; 1 = weak staining; 2 = moderate staining; 3 = strong staining. A final score was calculated by adding the scores for percentage-positive cells and intensity, resulting in a score of 0 or ranging from 2 to 7. This final score is categorized into: negative (0), weak (2-3) or strong (4-7).
Statistical analysis
The percentages loss on 3p, 1 q and 17p were correlated to each other and to FIGO stage, lymphnode positivity, tumour size, vasoinvasion and histology. With the chi-square test these percentages were evaluated. RESULTS LOH analysis on chromosomes 3, 11, 17, 13 and 16
All 64 carcinomas were analysed for the same polymorphic markers on chromosome 3, 11, 17, 13 and 16. Table 1 shows the list of polymorphic markers used, their map positions, the proportion of informative cases among tumours studied and the frequency of LOH at each locus. Figure 1 shows representative films demonstrating LOH at several loci. Among the loci that had LOH, the frequency varied widely, ranging from 4% [D17S855 (BRCA1)], D13S153 (RB)] on chromosome 17q and 13q to 46% (DlIS35) on chromosome llq. Chromosome arms llq, 3p, and 17p had LOH in more than 25% of tumours. Figure 2 shows the LOH patterns found on chromosomes 3, 11 and 17. Nine tumours did not have LOH on any of the chromosome arms studied. Additional markers were used for those chromosome arms that had frequent LOH, i.e. chromosomes 3 and 11.
Chromosome 3p
On the short arm of chromosome 3, frequent LOH (40%) was found at 3p2l.1 (D3S 1289). The smallest region of overlap was on 3p2l-3p23. Using the additional markers in this region we could decrease the smallest region of overlap for LOH between an intra- Figure 3) .
Chromosome 1 1q
The 34 tumours with LOH for chromosome lq were tested for Chromosome 17p additional markers. Figure 3 shows the results of this screening.
On chromosome 17pl3.3 a marker (D17S513) distal to the p53 Among the markers tested, LOH was most frequent in these 34 tumour-suppressor gene had 38% LOH. TP53, a marker within tumours at Dl 1S35 (79%), Dl 1S938 (7 1%) and Dl 1S528 (74%).
the p53 coding region, had 20% LOH. In ten cases there is a British Journal of Cancer (1998) 77(2) 
Microsatellite instability
In addition to LOH, microsatellite instability was observed in 9 out of 64 cases ranging from 1-15 affected loci in 24 microsatellite markers, resulting in increased or decreased size of one or both alleles. All cases also had LOH at other loci. Two had microsatellite instability at three loci, whereas six cases were affected at only one locus. The remaining tumour (CT73) had microsatellite instability for almost all loci, except for one locus, D16S752, which had LOH (Figure 4 ).
,-Catenin and E-cadherin expression
The 0-catenin gene is located on chromosome 3p2l and an intragenic polymorphic 0-catenin microsatellite marker shows frequent LOH. Therefore, P-catenin is a potential tumour-suppressor gene in cervical carcinomas. Inactivation of the 3-catenin gene is expected to result in loss of expression of the ,B-catenin protein, and therefore we investigated ,B-catenin expression using immunohistochemistry. P-Catenin expression was strong in 32, weak in six cases and completely negative in one case (Table 2 and Figure 5 ). . E-cadherin expression was also studied in this tumour series. Strong E-cadherin expression was found in 31 of 37 cases, and six cases had weak expression. Complete absence of Ecadherin expression was never observed. There was no association between the level of P3-catenin and E-cadherin expression.
Correlation with tumour characteristics
In Table 3 the different clinical and histological parameters are correlated to losses on chromosome 3p, llq and 17p. As can be seen in Table 3 , the only significant correlation was for histological type and loss on chromosome 3p. LOH on chromosome 3p was observed in 54% of squamous carcinomas and in none of six adenocarcinomas. The LOH data were also correlated with respect to each other, but there is no correlation between the different losses.
DISCUSSION
We have identified three chromosome regions that are likely to harbour tumour-suppressor genes important in the tumorigenesis of cervical cancer. Frequent LOH (41%) on chromosome 3p was found in the region between the ,B-catenin gene and marker D3S 1289. Thus, we narrowed down the region of LOH to approximately 15 cM. The f-catenin gene is located in this smallest region of overlap. With the intragenic marker for ,-catenin we found 37% LOH, which points to a possible role for this gene in cervical cancer. If the 3-catenin gene would be inactivated by LOH and mutational inactivation, complete loss of 0-catenin protein expression is expected. This was only found in one case. Mutation analysis by single-strand conformation polymorphism will be performed on the one tumour that had loss of 1-catenin expression and ,-catenin, staining is located at the plasma cell membrane. N, normal squamous epithelium; T, tumour tissue. Normal epithelium serves as an internal positive control for both f-catenin and E-cadherin staining and in the six cases with weak expression. In colon cancer and melanoma, it has been described that B-catenin can be stabilized and become unbound to APC by mutations in the tumoursuppressor gene APC or in ,-catenin itself. If the association between APC and ,-catenin is released, this will promote formation of ,-catenin-Tcf complexes, which are translocated to the nucleus and activate gene transcription.
Various groups have studied chromosome 3p in cervical carcinomas, and 3p21-22 was a common region of LOH (Mullokandov et al, 1996) . The marker most used and lost in this region is D3S2. It is located between D3S 1289 and D3S 1768, which we used. This region is also frequently involved in LOH in other tumours (breast, lung, kidney) . In addition to the P-catenin gene, other candidate (tumour-suppressor) genes are located in this area, for instance TGM-4 (Gentile et al, 1995) , which is the human prostate transglutaminase type IV gene whose function has been associated with the mammalian reproductive system and hMLH-1 (Bronner et al, 1994; Hemminki et al, 1994; Papadopolous et al, 1994) , a human DNA mismatch repair gene involved in human non-polyposis colorectal cancer (HNPCC) families. However, LOH on 3p2l-22 is not associated with the RER phenotype. Our results indicate that an as yet unidentified gene between ,-catenin and D3S 1289 most probably functions as a tumour-suppressor gene in cervical cancer that may also be involved in other tumour types. Further mapping will be required to identify this gene.
The E-cadherin gene is located on chromosome 16q22.1 and is a prime mediator of cell-cell adhesion in epithelial cells. This tumour-suppressor gene was studied because of its interaction with the f-catenin protein. We found six cases that had weak expression of E-cadherin; total loss of expression was not seen.
LOH for 16q22.1 was sporadically found (10-14%) in the 64 cases studied. Others Vessey et al, 1995) have studied the expression of E-cadherin in normal cervical epithelium, CIN lesions, cervical carcinomas and metastases. These groups found that there was altered expression of E-cadherin in some CIN lesions and some tumours. The results from the different groups and our results suggest that alterations in the E-cadherin gene are not of major importance in cervical carcinomas. (1994) described about 44% loss of the region llq22-q24 but used only five markers in this area, which are located in the same region as the markers used by us. Bethwaite et al (1995) used only one marker (DI lS29) in this area, which had 30% loss. This marker is located at the same chromosome region as Dl S528 used in these experiments. The region between 1 lq22-q24 is also involved in other tumours, including malignant melanoma (Tomlinson et al, 1993) , breast cancer, colorectal cancer (Keldysh et al, 1993) , ovarian cancer (Foulkes et al, 1993) and paragangliomas (Mitra et al, 1994; Mullokandov et al, 1996) . In contrast, frequent LOH was found on 17pl3.3 with two markers D17S513 (38%) and D17S1537 (32%). Park et al (1995) found 40% LOH with one of two markers (D17S34 and D17S5) used on 17pl3.3. These markers are placed approximately 19 cM from our markers. This region also shows frequent LOH in a number of different tumours, such as carcinomas of the bladder, ovary, breast, malignant medulloblastomas, hepatocellular and medulloblastomas (Comelis et al, 1994; Morris et al, 1995 Wales et al, 1995) . In one study of breast cancer, the independent loss of 17pl 3.3 alleles was accompanied by increased levels of p53 mRNA, which suggests that the 17pl3.3 tumour-suppressor gene may regulate p53 expression (Coles et al, 1990) . From our results and the results of others it is clear that a tumour-suppressor gene that is important for cervical carcinomas must be present on chromosome 17pl3.3. Recently, it was found that tumours can have a RER (replication error) phenotype, pointing to malfunctioning of the DNA repair and replication mechanisms. Clearly, RER-positive tumours are defined as tumours that have microsatellite instability in at least two out of the seven microsatellite loci (Burks et al, 1994) . One tumour in our series meets these criteria. RER is often found in colorectal cancers, colon, endometrial (Burks et al, 1994) and ovarian cancers (Orth et al, 1994; Liu et al, 1995) . In cervical cancer, two groups (Mitra et al, 1995; Larson et al, 1996) reported microsatellite instability. Mitra et al (1995) , reported this phenomenon only at a few loci on chromosome 5. Larson et al (1996) studied three different chromosomes in 89 primary cervical tumours and found RER+ phenotypes in 5.6% of cases. In our series, we found nine cases (14%) that had microsatellite instability at various loci, and LOH was shown in all these cases.
In conclusion, we have provided additional evidence for the probable presence of at least three tumour-suppressor genes in squamous cell carcinomas of the uterine cervix: one at 3p2l, one at l7pl3.3 and one to possibly three at chromosome 11. We will continue mapping the smallest region of LOH in these tumours and analyse candidate genes present in the regions of LOH. We have confirmed the presence of microsatellite instability in approximately 14% of cervical carcinomas.
